Considering the impact of SGLT2i on CIAKI, it may be related to the duration of SGLT2i use and considering that there was no difference in the prevention of AKI or the time of recovery from CIAKI by SGLT2i.The difference in long-term outcomes could be related to the beneficial effects of the SGLT2 inhibitor itself rather than its effects on CIAKI. The gene discussed is SLC5A2; the disease is acute kidney injury.